Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q96DV4
UPID:
RM38_HUMAN
Alternative names:
39S ribosomal protein L38, mitochondrial
Alternative UPACC:
Q96DV4; B3KN96; Q96Q66; Q9P0B9
Background:
The Large ribosomal subunit protein mL38, also known as 39S ribosomal protein L38, mitochondrial, plays a crucial role in the mitochondrial ribosome. It is part of the machinery responsible for protein synthesis within mitochondria, implicating its importance in cellular energy metabolism and mitochondrial function.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein mL38 could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis suggests that modulation of its activity could have implications for diseases related to mitochondrial dysfunction.